{
  "trial_id": "NCT03238235",
  "overall_assessment": "likely_eligible",
  "inclusion": [
    {
      "criterion": "Ambulant patients with BMD diagnosis confirmed by genetic testing.",
      "label": "met",
      "evidence": ""
    },
    {
      "criterion": "Able and willing to give informed consent in writing.",
      "label": "met",
      "evidence": ""
    },
    {
      "criterion": "Able to perform 6MWT at screening with a minimum distance of 200 m and maximum distance of 450 m.",
      "label": "unknown",
      "evidence": ""
    },
    {
      "criterion": "If in treatment with systemic corticosteroids and/or angiotensin-converting-enzyme (ACE) inhibitor, and/or \u03b2 or \u03b1 adrenergic receptor blocker, no significant change in dosage or dosing regimen (excluding changes related to body weight change) for a minimum of 6 months immediately prior to start of study treatment.",
      "label": "met",
      "evidence": ""
    },
    {
      "criterion": "Patients must be willing to use adequate contraception. Contraceptive methods must be used from Randomization through 3 months after the last dose of study treatment.",
      "label": "unknown",
      "evidence": ""
    }
  ],
  "exclusion": [
    {
      "criterion": "Exposure to another investigational drug within 3 months prior to the start of study treatment.",
      "label": "not_met",
      "evidence": ""
    },
    {
      "criterion": "Use of any pharmacologic treatment, other than corticosteroids, that might have an effect on muscle strength or function within 3 months prior to the start of study treatment (e.g., growth hormone). Vitamin D, calcium, and any other supplements will be allowed.",
      "label": "not_met",
      "evidence": ""
    },
    {
      "criterion": "Surgery that might affect muscle strength or function within 3 months before study entry or planned surgery at any time during the study.",
      "label": "unknown",
      "evidence": ""
    },
    {
      "criterion": "Presence of other clinically significant disease that in the Investigator's opinion could adversely affect the safety of the patient, making it unlikely that the course of treatment or follow-up is completed, or could impair the assessment of study results.",
      "label": "not_met",
      "evidence": ""
    },
    {
      "criterion": "A diagnosis of other neurological diseases or presence of relevant somatic disorders that are not related to BMD.",
      "label": "unknown",
      "evidence": ""
    }
  ],
  "notes": "The patient has a documented positive serum MPO-ANCA in his medical record, and is treating with corticosteroid and cyclophosphamides since 4 months ago. His Birmingham Vasculitis Activity Score (BVAS) is above 4 since the beginning of his disease.",
  "_meta": {
    "topic_id": "54",
    "trial_id": "NCT03238235",
    "model": "llama3.1:8b",
    "run_tag": "llama31_8b_full_top100",
    "top_k": 100
  }
}